Evaluating Independent Tumor Measurement Treatment Response Vendors - And Why We Chose to Stay In House

Erika Waalkes, Kathryn Allen, Priyanka Koya, Nadia Chowdhury, Brianne Bodin, BSN, Ankeeta Joshi, Janice Mehnert, MD, Bhavana Pothuri, MD

Background:
Cancer centers utilize various tools to assess tumor measurements and response, including: radiology scan reports reviewed by investigator, independent dedicated in-house trained radiologists, and external vendors. Prior to Fall 2023, NYU relied on investigators to complete response forms based on scan reports. This lead to a large number of discrepancies such as, missing lesion measurements (40%), incomplete dimension measurements (29%), discrepancies in previous measurements (22%), and typos (9%) (n=35). Overall 55% (n=64) of reports had some issue that required study team to follow up with dedicated team. In 2022, NYU CTO began exploring alternative approaches such as engaging independent reviewers to reduce bias in treatment effect estimation delegated to investigators1.

Specific Aims
- Not investing in NYU
- Building process from start
- Pricing and cost
- Investing in NYU
- + vetted process in place
- Building process from start
- + pricing and cost
- Investing in NYU
- Building process from start
- + vetted process in place

References:

Outcomes:

- Since Fall of 2023, we assigned our in-house independent radiologists to complete tumor assessment forms with the aim of reducing bias in the interpretation process and improving data quality. In the initial stages of this transition, we have already observed:
  - A decrease in discrepancies in reports, down to 15% (n=34) from 55% (n=64).
  - Having a well-trained dedicated team has also led to reduction in communications required when addressing any discrepancies, range of communications in old workflow was 1 to 6 email communications. New workflow is only requiring 1 email communication.
  - Another positive, is retaining funding within our institution.

- Various external companies were evaluated based on factors such as annual and per time-point fees, turnaround time, and communication channels. Concurrently, a new radiology team with expertise in oncology clinical trials was hired, and after consulting with the new leadership regarding overall cost and support, the decision was made to keep workflow in-house as it was most expedient. The implementation of this decision as of November 2023 has been a multistep project. Specifically, unique orders in the electronic medical record (EMR), which prompt the radiology team to read a specified scan (either ongoing or prior) per tumor guidelines and email a detailed report to the study team.

- Order is placed with tumor measurement requirement when scan is ordered.

- Scan is read clinically and read by dedicated radiology team per particular tumor measurement guidelines. This is sent to research team. *Baseline lesions are often discussed between investigator and radiologist.*

- Measurements and calculations are verified with team and investigator and transferred on to tumor measurement worksheet.

Future

Stage 2: Clinical Research Nurses have begun taking an active role in entering scan orders, including trial specific details, further aiming to reduce discrepancies.

Stage 3: The future goal of this project is to transition the radiology team from the current practice of emailing the study team the assessments to having them upload the worksheet directly to the EMR.

Goals:

- Ensure accurate and efficient tumor measurements at each time point.

- External vendors
  - + vetted process in place
  - - Pricing and cost
  - - Not investing in NYU

- In-house Dedicated Core
  - - Radiology Group
  - + - + Pricing and cost
  - + - Investing in NYU
  - + - Building process from start
  - + - + + vetted process in place

Contact for more information:
Erika.Waalkes@nyulangone.org
Brianne.Bodin@nyulangone.org